Axatilimab is a colony-stimulating factor-1 receptor–blocking monoclonal antibody indicated after 2 lines of systemic therapy.
Stephen Eng, PharmD, BCOP
Advertisement
Articles by Stephen Eng, PharmD, BCOP
Treatment selection includes patient factors, cost, adverse effects, and drug interactions.
Treatment often involves a combination of preventive measures, topical therapies, and systemic treatments.
Advertisement
Latest Updated Articles
New Therapy for Chronic Graft-Vs-Host Disease: AxatilimabPublished: February 21st 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
FDA Initiates Approval of Leucovorin for Patients With Cerebral Folate Deficiency
2
Rapid CAR T Expansion Linked to Delayed Neurotoxicity in Patients Treated With Cilta-Cel
3
Hercessi, Biosimilar to Herceptin, Shows Favorable Efficacy, Safety in Treating HER2+ MBC in Real-World Setting
4
IMS: Shaping the Future of Multiple Myeloma with Anti-CD38 Quadruplets
5
